Linvoseltamab

ASCO 2023: Pretreated myeloma patients exhibit a high response rate and manageable toxicity when treated with Linvoseltamab.

ASCO 2023: How Linvoseltamab Can Treat Pretreated Myeloma Patients

SG Tylor

ABSTRACT NUMBER – 8006 Linvoseltamab, an investigational bispecific antibody known as BCMAxCD3, shows promising potential in connecting B-cell maturation antigen ...